These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 25415284

  • 1. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.
    J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
    [Abstract] [Full Text] [Related]

  • 2. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.
    Sci Transl Med; 2015 Mar 18; 7(279):279ra41. PubMed ID: 25787767
    [Abstract] [Full Text] [Related]

  • 3. BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.
    Dörrie J, Babalija L, Hoyer S, Gerer KF, Schuler G, Heinzerling L, Schaft N.
    Int J Mol Sci; 2018 Jan 18; 19(1):. PubMed ID: 29346301
    [Abstract] [Full Text] [Related]

  • 4. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS.
    Cancer Immunol Res; 2014 Apr 18; 2(4):351-60. PubMed ID: 24764582
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
    Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.
    Clin Cancer Res; 2013 Mar 01; 19(5):1225-31. PubMed ID: 23307859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S, Takahashi M, Yoshida Y, Yamada H, Komine K, Ishioka C.
    Cancer Sci; 2021 Sep 01; 112(9):3856-3870. PubMed ID: 34288281
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):140. PubMed ID: 29986755
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
    Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A.
    Cancer Res; 2012 Aug 15; 72(16):3928-37. PubMed ID: 22693252
    [Abstract] [Full Text] [Related]

  • 17. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 18. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.
    Biochem Pharmacol; 2015 May 01; 95(1):16-27. PubMed ID: 25795251
    [Abstract] [Full Text] [Related]

  • 19. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J, Larkin J.
    Future Oncol; 2015 May 01; 11(4):579-89. PubMed ID: 25686114
    [Abstract] [Full Text] [Related]

  • 20. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, Schiavoni G, Fortini E, Spanhol-Rosseto A, Sportoletti P, Mannucci R, Martelli MP, Klein-Hitpass L, Falini B, Tiacci E.
    Blood; 2015 Feb 19; 125(8):1207-16. PubMed ID: 25480661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.